500087 Forex-Nachrichten
Exelixis Resolves Two CABOMETYX Patent Disputes With Cipla
Exelixis, Inc. (EXEL) announced Monday that it has entered into a Settlement and License Agreement with Cipla Ltd. and Cipla USA, Inc. to resolve two patent litigations brought by Exelixis in response to Cipla's Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of CABOMETYX (cabozantinib) tablets prior to the expiration of the applicable patents.
RTTNews
|
vor 181 Tagen
